Frede, Natalie http://orcid.org/0000-0002-6415-6376
Hiestand, Sonja
Schauer, Franziska
Endres, Dominique
Tebartz van Elst, Ludger
Zeisbrich, Markus
Craig-Mueller, Nils
Finzel, Stephanie
Thiel, Jens
Voll, Reinhard E.
Schempp, Christoph
Venhoff, Nils
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 17 July 2023
Accepted: 20 September 2023
First Online: 15 October 2023
Declarations
:
: Nils Venhoff: Speaker honoraria: AbbVie, Novartis, UCB, Bristol-Myers Squibb, Pfizer; Advisory Boards: AbbVie, Novartis, UCB; Research grants: Bristol-Myers Squibb, Novartis, Pfizer. Jens Thiel: Speaker honoraria: GSK, BMS, AstraZeneca, Abbvie, UCB, Lilly; Advisory Boards: Novartis, GSK, AstraZeneca, Lilly. Grant/research support from: BMS, Novartis. Reinhard E. Voll: Speaker fees: AbbVie, Amgen, BMS, Boehringer-Ingelheim, GSK, Janssen-Cilag, Hexal, Novartis, Pfizer, Roche; Advisory boards: AbbVie, Amgen, Boehringer-Ingelheim, BMS, GSK, Janssen-Cilag, Hexal, Neutrolis, Novartis, Sanofi, Takeda; Unrestricted research grants: Amgen, BMS, Novartis, Pfizer. Natalie Frede received travel grants from AbbVie, Janssen, Sobi, Pfizer. Sonja Hiestand, Franziska Schauer, Dominique Endres, Ludger Tebartz van Elst, Markus Zeisbrich, Nils Craig-Mueller, Stephanie Finzel and Christoph Schempp have nothing to declare.
: The study was conducted under the ethics protocol 190/17 (ethics committee of the University of Freiburg, Germany). Patients gave their written consent according to International Conference on Harmonization Good Clinical Practice (ICH GCP) guidelines. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.